INTRODUCTION
============

The early spread of tumor cells among breast cancer patients is usually undetectable, even by conventional pathologic analyses and high-resolution imaging technologies. With highly sensitive immunocytochemical and molecular assays, it is possible to detect occult metastatic tumor cells at the single-cell stage in peripheral blood, regional lymphatic nodes, and bone marrow before incurable distant metastases occur.[@B1] Circulating tumor cells (CTCs) circulate in the peripheral blood of patients. CTCs can originate from both the primary tumor and its metastases. It is believed that CTCs mediate the hematogenic spread of cancer to distant organs, including bone, lung, brain, and liver. CTCs have potential to form metastases, and for this reason, they can be useful predictors of poor outcomes, such as shorter disease-free and overall survival.[@B2][@B3][@B4] Furthermore, checking CTC levels may be valuable for follow-up evaluation and to monitor therapeutic efficacy.[@B1][@B5][@B6][@B7]

Immunocytochemistry using antibodies against proteins, which are not expressed in mesenchymal cells, but in epithelial cells, is commonly used for the detection of CTCs. In recent studies, reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative real-time RT-PCR methods have shown higher diagnostic sensitivity.[@B8][@B9][@B10] The development of real-time RT-PCR technology has allowed an enormous progress in cancer diagnostics, providing significant and quantitative data about gene expression in an automated, fast, flexible, affordable, and cost-effective way. Real-time RT-PCR has recently been used to detect CTCs in the peripheral blood and lymph nodes in patients with metastatic breast cancer through the detection of differential expression of marker genes, which are achieved by multigene RT-PCR assays, respectively.[@B10][@B11]

In this study, we report an adaptation and analytical validation of a real-time quantitative RT-PCR methodology for cytokeratin (CK)-19 mRNA using the LightCycler system.[@B8][@B12] CK-19 is a typical epithelial marker, which is present in epithelial cells, but is not found in mesenchymal cells. It has been investigated extensively as a potential marker to detect CTCs in early and metastatic breast cancer.[@B3][@B10][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24] Among the numerous molecular markers currently being used to detect occult micrometastasis indirectly in patients with breast cancer, detecting CK-19 mRNA expression is considered one of the most promising methods to detect CTCs, due to its high sensitivity and specificity.[@B11]

MATERIALS AND METHODS
=====================

Cell samples
------------

The human breast cancer cell lines including MCF-7, SK-BR-3, and MDA-MB-231 (obtained from the Korean Cell Line Bank, Seoul, Korea), which contain the CK-19 gene, were used as positive controls. Each of the cell lines was cultured in Dulbecco\'s modified eagle medium containing 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin (HyClone, Logan, UT, USA).

Patients and blood samples
--------------------------

From October 2010 until February 2012, a total of 242 consecutive patients with breast cancer (median age 53 years, 26--83 years), including 69 patients with early breast cancer (stage I--II, 28.5%), 47 patients with locally advanced breast cancer (19.4%), and 126 patients with metastatic disease (stage IV, 52.1%), were enrolled to identify detection rates of CTCs according to tumor burden. To evaluate clinical relevance, blood samples were collected after surgery or before adjuvant therapy in early breast cancer patients, at initial diagnosis in locally advanced breast cancer patients and at implementation of therapy or the regimen change for disease progression in metastatic patients. All patients with locally advanced breast cancer received neoadjuvant chemotherapy before surgery.

To serve as controls, 30 healthy female donors were recruited (median age 47 years, 30--54 years) and blood samples were obtained. Peripheral blood (12.5 mL in ethylenediaminetetraacetic acid) was obtained from healthy volunteers and breast cancer patients. The blood samples were conditioned at 4℃ for different time intervals and processed within a maximum of 24 hours after the samples were drawn. To avoid epithelial contamination by the skin, the first 5 mL of each blood sample was discarded. Prior to participation in this study, patients and healthy donors provided informed consent, approved by the Ethics and Scientific Committees of our institution (IRB ID number=4-2011-0011).

Total RNA isolation and cDNA synthesis
--------------------------------------

Isolation of total RNA was processed using the Trizol LS reagent (Gibco-BRL, Carlsbad, CA, USA) according to the manufacturer\'s instructions. All RNA preparation and handling procedures were performed in a laminar flow hood under RNase-free conditions. Isolated RNA was dissolved in RNA storage buffer (Life Technologies, Carlsbad, CA, USA) and stored at -80℃ for further processing. The RNA concentration was evaluated by absorbance readings at 260 nm using a NanoDrop spectrophotometer (Thermo Scientific, Fremont, CA, USA). RNA integrity was tested by PCR amplification of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping gene. Reverse transcription of RNA was carried out with the Omniscript Reverse Transcription RT kit (QIAGEN, Hilden, Germany). Total RNA prepared from the MCF-7 cell line was used as a positive control. cDNA was synthesized from 5 µg of total RNA isolated from peripheral blood mononuclear cells of healthy donors and breast cancer patients, according to the manufacturer\'s instructions.

Real-time RT-PCR amplification
------------------------------

Quantification is based on real-time monitoring during PCR of fluorescently labeled specific probes for CK-19. Real-time RT-PCR for CK-19 mRNA was performed using the LightCycler system 480 (Roche, Penzberg, Upper Bavaria, Germany). Real-time RT-PCR was conducted in a total volume of 20 µL, containing 2 µL of cDNA, 0.3 µg of the CK-19 forward primer (10 pM), 0.3 µL of the reverse primer CK-19 (10 pM), 0.3 µL of the probe CK-19 (10 pM), and 10 µL of LightCycler 480 Probes Master mix reagent (2X, Roche, Penzberg, Upper Bavaria, Germany). Finally, diethylpyrocarbonate (DEPC)-H2O was added to the reaction mix. All primers and hybridization probe sequences are listed in [Table 1](#T1){ref-type="table"}.

PCR reaction was initiated after a 10-minute denaturation at 95℃, and then the cycling protocol, consisting of denaturation at 95℃ for 10 seconds, and annealing at 60℃ for 30 seconds, was repeated 50 times. Fluorescence detection was performed at the end of each annealing step for 0.25 second.

For quantification, an external standard curve was applied using cDNA from MCF-7 cells, which was described in previous studies.[@B8][@B12] Total RNA was obtained from 1×10^6^ MCF-7 cells through serial dilution.[@B8][@B12] This cDNA was used as the CK-19-positive control. This standard curve was created by plotting the number of MCF-7 cells corresponding to each value of its Ct.[@B8][@B12]

The proposed real-time RT-PCR methodology was applied in a total of 272 peripheral blood samples collected from 30 healthy female donors, 69 patients with early breast cancer after surgery or before adjuvant therapy, 47 patients with locally advanced breast cancer, and 126 patients with verified metastasis before regimen change or first-line chemotherapy.

The amount of total RNA in each sample was used to normalize our real-time RT-PCR data. We adopted the previous detection limit method to set up the cutoff of CTC detection.[@B8] The presence of ≥0.792 MCF-7 cell equivalents/5 µg RNA in the patient blood sample was considered a positive result on the basis of the analytical detection limit. According to this cutoff, the specificity of the proposed method was evaluated by analyzing peripheral blood samples from 30 female healthy donors.

Primary data analysis
---------------------

Real-time RT-PCR data was quantified as Ct values that are inversely related to the amount of starting template: high Ct values were correlated with low levels of gene expression, whereas low Ct values were correlated with high levels of gene expression. Results were normalized to an internal control reference gene. If the mean Ct value for CK-19 mRNA was higher or equal to 36, the CK-19 expression was considered undetectable. To define the baseline levels of CK-19 expression and thresholds for CK-19 positivity, 30 specimens of peripheral blood mononuclear cells obtained from female healthy donors with no evidence of malignancy were analyzed. The molecular analysis was blinded to clinical outcome and patient clinicopathological data.

Tumor stage was based on the American Joint Committee on Cancer Staging manual 6th edition. Histological grade was assessed based on the modified Bloom-Richardson classification. Tumors with ≥1% nuclear-stained cells were considered to have estrogen receptor (ER) and progesterone receptor (PR) positivity. Human epidermal growth factor receptor (HER2) overexpression was considered positive in cases with an immunohistochemistry (IHC) score of 3+ or gene amplification by fluorescence *in situ* hybridization with an IHC score of 2+.[@B25] Breast cancer subtypes, based on ER, PR, and HER2, were categorized into three subtypes: those that were ER- and/or PR-positive were classified as the luminal subtype; those that were ER- and PR-negative and HER2-positive were classified as the HER2 subtype; and those that were negative for all markers were classified as triple-negative breast cancer.

Statistical analysis
--------------------

SPSS version 20.0 (IBM, Armonk, NY, USA) statistical software was used for the analysis of pathological and molecular outcome. Chi-square tests were conducted to explore the association between pre-defined baseline categorical covariates and real-time RT-PCR positivity/negativity status. t-test or ANOVA was used to compare continuous variables. Pre-defined baseline covariates were age, TNM stage, histological grade, ER status, PR status, and HER2 status. Statistical significance was defined as *p* values\<0.05. All tests were two-sided.

RESULTS
=======

Detection rates
---------------

The real-time RT-PCR method based on CK-19 mRNA showed 100% specificity, because none of the 30 blood samples from healthy donors had detectable CK-19 mRNA positive cells.

In 69 patients with early breast cancer, CK-19 mRNA positive cells were detected in 33 patients (47.8%). Among the 47 patients with locally advanced breast cancer, 22 (46.8%) patients were found to be positive prior to neoadjuvant chemotherapy. CK-19 mRNA positive cells were detected in 77 (61.1%) patients among the 126 patients with distant metastasis. The Ct values observed in patients with breast cancer who had detectable CK-19 mRNA, classified according to treatment groups, are illustrated in [Fig. 1](#F1){ref-type="fig"}. There was no significant difference in terms of Ct values according to the treatment group (*p*=0.164) ([Fig. 1](#F1){ref-type="fig"}).

Patient characteristics
-----------------------

The mean age of all patents was 52.1±10.4 years. Mean ages according to tumor burden were 53.1±9.7 years in patients with early breast cancer, 50.1±11.4 years in patients with locally advanced cancer, and 52.3±10.4 years in patients with distant metastasis. There were no significant differences in age according to tumor burden.

The distribution of patient demographic and clinicopathological characteristics is shown in [Table 2](#T2){ref-type="table"}. The rates of CTC-positive cells were not different between patients younger than 50 years and those aged 50 years and older. Patients with distant metastasis had a CTC detection rate of 61.1% in their blood samples; meanwhile, patients with early and locally advanced breast cancer had detection rates of 47.8% and 46.8%, respectively. CTCs were more often observed in ER-negative tumors than in ER-positive tumors (60.8% vs. 51.0%, respectively). In terms of breast cancer subtypes, CTCs were more commonly detected in patients with TNBC than other subtypes (63.3% vs. 47.5--55.0%). All clinicopathological features were not significantly associated with the detection of CTCs, as defined by CK-19 mRNA positive cells ([Table 2](#T2){ref-type="table"}).

[Table 3](#T3){ref-type="table"} shows the detection rates of CK-19 mRNA-positive cells according to metastatic sites in patients with distant metastasis. CTCs were more frequently identified in patients with visceral metastasis than in those with non-visceral metastasis (61.5% vs. 58.6%); however, this difference was not significant (*p*=0.784). Patients with pleural metastasis demonstrated significantly higher CTC detection than those without pleural metastasis (*p*=0.04) All other metastatic sites were not associated with CK-19 mRNA-positive CTCs.

Overall survival according to CK-19 mRNA-positive CTCs
------------------------------------------------------

Overall survival curves according to CK-19 mRNA-positive cells are shown in [Fig. 2](#F2){ref-type="fig"}. With a median follow-up period of 29 months (range, 0--44 months), survival was poorer in patients positive for CTCs than in those without detectable CTCs, and the difference was significant (*p*=0.014). In multivariate analysis adjusting for age, CTC detection, and tumor burden, only metastatic tumor burden was significantly associated with overall survival \[*p*\<0.001, hazard ratio (HR)=27.014, 95% confidence interval (CI)=8.524--85.617\]. Binary CTC detection (yes or no) was not a significant prognostic factor for overall survival in multivariate analysis (*p*=0.097, HR=0.700, 95% CI=0.459--1.067) ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

CTCs are epithelial tumor cells detected in the peripheral blood of patients with solid tumors using mainly immunocytochemical approaches including CellSearch (Veridex LLC, Raritan, NJ, USA) and AdnaTest (AdnaGen AG, Langenhagen, Germany).[@B1][@B10][@B26] CellSearch is the only technology for CTC detection that has been admitted by the Food and Drug Administration as an aid in monitoring patients with metastatic breast, colorectal, and prostate cancers. However, CellSearch has a limitation that is inherent in its immunomagnetic enrichment system. EpCAM-negative CTCs can be excluded during the test using CellSearch, because CellSearch is based on the magnetic detection of EpCAM-positive cells. Some investigators have pointed out heterogeneous expression of EpCAM in breast cancer and down-regulation of EpCAM after chemotherapy.[@B27] Thus, detection systems that use RT-PCR for CK or multiple markers that can identify the presence of CTCs, regardless of EpCAM expression, have been investigated in several studies.[@B8][@B12][@B13][@B14][@B22][@B24] Compared to the CellSearch immunomagnetic enrichment system, RT-PCR for CK or other multimarkers exhibits superior sensitivity.[@B10] In this study, CK-19 mRNA expression was detected in more than half of patients with metastatic disease and about half of patients with early breast cancer, and these results were similar to those of a previous study.[@B14] The detection rate of CTCs using the Cellsearch system was about 20--30% in patients with breast cancer.[@B10][@B28] The detection rate of RT-PCR for CK-19 mRNA expression in the current study was almost two-fold higher than that of CellSearch. However, there was no standardized technique for detecting CK-19 mRNA-positive CTCs among previous studies that used CK-19 mRNA expression to report on the presence of CTCs, and considerable heterogeneity of detection methods existed in previous studies.[@B8][@B11][@B12] Therefore, caution is required in the interpretation and application of RT-PCR for the detection of CK-19 mRNA expression.

The relationships observed between the presence of CTCs and clinicopathological parameters were different in different studies due to heterogeneity of the study design.[@B11][@B13][@B14][@B20][@B22][@B23][@B26] The meta-analysis conducted by Zhao, et al.[@B11] revealed that CTC-positive tumors were associated with biologically aggressive phenotypes; on the other hand, CK-19 mRNA-positive breast cancers were not. Several studies also reported no relation between the presence of CK-19 mRNA-positive CTCs and clinicopathological parameters, including age, tumor size, ER, PR, HER2, and grade,[@B13][@B14][@B20][@B22][@B23] and only the tumor burden was related to presence of CTCs.[@B13][@B22] Previous studies reported that more CTCs were detected in metastatic disease than in early disease.[@B13][@B22] Our study showed no relationship between the presence of CK-19 mRNA-positive CTCs and clinicopathological parameters with the exception of pleural metastasis, and this is partially concordant with a previous study.[@B29] The lack of agreement between the current study and previous studies in the literature may be due to the difference in defining CTCs and the lack of standardized techniques for RT-PCR of CK-19 mRNA.

The current study demonstrated that patients with CK-19 mRNA CTC detection showed poorer survival than those without detection in univariate analyses; however, this did not hold up on multivariate analyses. Stathopoulou, et al.[@B14] suggested that CTC detection by CK-19 mRNA expression is related to poor survival. Benoy, et al.[@B22] also reported that elevated CK-19 in bone marrow is prognostic; however, the peripheral CK-19 level is not. Although there are some similarities in detection techniques between previous and current studies, the prognostic values of CTC detection using CK-19 mRNA expression varies among studies. This discordance among studies may be due to heterogeneity in the study design: the Greek study mainly included metastatic breast cancer,[@B14] whereas the Belgian study enrolled more patients with early breast cancer than with metastatic breast cancer.[@B26] We enrolled 129 patients with metastatic breast cancer; this constituted about half (52.1%) of all patients. These discrepancies among the studies may have caused the difference in outcomes. Recently, a large prospective multicenter study confirmed that CTC detection by the CellSearch system in patients with early breast cancer is also clinically relevant and prognostic.[@B28] In the current study, it was not possible to analyze patients with early and advanced breast cancer using subgroup analyses, due to the short follow-up duration. Therefore, further studies with longer follow-up periods are needed for the patients with early breast cancer in this cohort.

There are some limitations of this study. First, due to the retrospective nature of the study and its sample size, selection bias cannot be ruled out. Pleural metastases were frequently found in the CTC-positive diseases in the current study. However, the cases of pleural metastases were too few to make solid conclusions, and thus, further studies are needed. Second, the absence of a consensus for CTC definition or threshold using RT-PCR methods makes it difficult to apply the results of the study to clinical settings. Different definitions and thresholds among studies can have an influence on reproducibility of the clinical role of CTCs in breast cancer. Third, the sole use of CK-19 mRNA expression for the detection of CTCs in the current study could be a limitation of the study, because the use of a single marker for the detection of CTCs may not be solely representative of various types of CTCs that may be defined by the presence of other CK family proteins, such as CK-8 and -18, and because the use of CK-family as CTC markers can enhance the detection rate of CTCs.[@B30][@B31] A previous study indicates that RT-PCR for multiple markers, including HER2 and MUC1, which are closely related to the progression or development of breast cancer, can provide more prognostic or predictive information.[@B32] Furthermore, epithelial-messenchymal transition markers and stem cell markers can increase in CTCs.[@B33] Therefore, further study using RT-PCR for multiple markers is needed to extend our knowledge of CTCs. Finally, recent genomic, morphological, and cultural analyses including single-cell sequencing, CTC clusters, and conditionally reprogrammed cells using CTCs cannot be accessed using RT-PCR for CK-19 mRNA-positive CTCs.[@B34][@B35][@B36] Thus, new technology that can isolate morphological CTCs has been introduced to overcome these limitations.[@B37] Further studies using the enhanced technology may shed light on the role of complex behaviors of CTCs in tumor biology.

In conclusion, we adapted and validated a detection method for CTCs using RT-PCR for CK-19 mRNA expression. The current study suggested that CTC detection using RT-PCR for CK-19 mRNA expression may have a clinical impact on overall survival in patients with breast cancer. Even though clinicopathological parameters, including age, tumor size, nodal status, ER, PR, HER2, and the grade of the primary tumor, which are all known prognostic factors of breast cancer, were not related to CTC detection using RT-PCR for CK-19 mRNA expression, with the exception of pleural metastasis, breast cancer patients in which CTCs were detected showed poor overall survival in univariate analysis. Further studies are needed to clarify the clinical role of the RT-PCR approach for CTC detection in the peripheral blood of patients with breast cancer.
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![Ct values according to treatment setting in patients with CTCs. High Ct values correlated with low levels of gene expression, whereas low Ct values correlate with high levels of gene expression. The box plots represent the median, maximal, and minimal number of Ct values. There was no significant difference in terms of Ct values among three groups (*p*=0.16). CTC, circulating tumor cell; EBC, early breast cancer; LBC, locally advanced breast cancer; MBC, metastatic breast cancer.](ymj-58-19-g001){#F1}

![Overall survival according to the detection of CTCs defined by CK-19 mRNA-positive cells. CTC, circulating tumor cell; CK, cytokeratin.](ymj-58-19-g002){#F2}

###### Sequences of Primers and Hybridization Probes Used in This Study

![](ymj-58-19-i001)

  mRNA     Product size (bp)   Primer 5\'-3\'                  Probe 5\'-3\'                 
  -------- ------------------- ------------------------------- ----------------------------- ---------------------------------
  CK-19a   96                  GAT GAG CAG CTC CGA GGT TA      TCT TCC AAG GCA GCT TTC AT    CTG CGG CGC CCC TTC GTC T
  CK-19b   141                 CGG GAC AAG ATT CTT GGT         CGT TGA TGT CGG CCT CCA       TGT CCT GCA GAT CGA CAA CGC CC
  CK-19c   127                 ATG AAA GCT GCC TTG GAA GA      GCT CAC TAT CAG CTC GCA CA    ATC AGC GGT ATT GAA GCC C
  GAPDH    150                 CCA TCT TCC AGG AGC GAG ATC G   ATG GTG GTG AAG ACG CCA GTG   TCC ACG ACG TAC TCA GCG CCA GCA

CK, cytokeratin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

###### Patient Demographics according to the Detection of CTCs, Defined as CK-19 mRNA-Positive Cells

![](ymj-58-19-i002)

                      CTC   *p* value                
  ------------------- ----- ----------- ----- ------ -------
  Age 50                                             0.248
   \<50               39    41.1        56    58.9   
   ≥50                71    48.6        75    51.4   
  Tumor burden                                       0.101
   Early              36    52.2        33    47.8   
   Metastatic         49    38.9        77    61.1   
   Locally advanced   25    53.2        22    46.8   
  Stage                                              0.162
   I                  21    55.3        17    44.7   
   II                 11    45.8        13    54.2   
   III                28    53.8        24    46.2   
   IV                 49    38.9        77    61.1   
  Grade                                              0.931
   I                  11    50.0        11    50.0   
   II                 25    54.3        21    45.7   
   III                17    54.8        14    45.2   
  ER                                                 0.154
   Negative           31    39.2        48    60.8   
   Positive           77    49.0        80    51.0   
  PR                                                 0.577
   Negative           53    43.8        68    56.2   
   Positive           55    47.4        61    52.6   
  HER2                                               0.289
   Negative           78    43.8        100   56.2   
   Overexpression     32    51.6        30    48.4   
  Subtype                                            0.259
   Luminal            59    45.0        72    55.0   
   HER2               31    52.5        28    47.5   
   TNBC               18    36.7        31    63.3   

CTC, circulating tumor cell; CK, cytokeratin; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; TNBC, triple-negative breast cancer.

###### Metastatic Sites according to the Detection of CTCs, Defined as CK-19 mRNA-Positive Cells

![](ymj-58-19-i003)

                  CTC   *p* value               
  --------------- ----- ----------- ---- ------ -------
  Visceral                                      0.784
   Visceral       37    38.5        59   61.5   
   Non-visceral   12    41.4        17   58.6   
  Bone                                          0.320
   Negative       22    45.8        28   36.8   
   Positive       26    54.2        48   63.2   
  Lung                                          0.444
   Negative       26    53.1        35   46.1   
   Positive       23    46.9        41   53.9   
  Pleural                                       0.045
   Negative       39    81.2        49   64.5   
   Positive       9     18.8        27   35.5   
  Liver                                         0.945
   Negative       30    61.2        47   61.8   
   Positive       19    38.8        29   38.2   
  Brain                                         0.947
   Negative       35    72.9        55   72.4   
   Positive       13    27.1        21   27.6   
  Soft Tissue                                   0.749
   Negative       25    51.0        41   53.9   
   Positive       24    49.0        35   46.1   
  Other                                         0.050
   Negative       46    93.9        62   81.6   
   Positive       3     6.1         14   18.4   

CTC, circulating tumor cell; CK, cytokeratin.

###### Multivariate Analysis according to the Detection of CTC, Defined as CK-19 mRNA-Positive Cells

![](ymj-58-19-i004)

                               *p* value   HR       95% CI   
  ---------------------------- ----------- -------- -------- --------
  Age (\<50 vs. ≥50)           0.315       0.806    0.529    1.227
  CTC detection (no vs. yes)   0.097       0.7000   0.459    1.067
  Tumor burden                                               
   Early                       Ref.                          
   Metastatic                  \<0.001     27.014   8.524    85.617
   Locally advanced            0.54        0.493    0.051    4.746

CTC, circulating tumor cell; CK, cytokeratin; HR, hazard ratio; CI, confidence interval.
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